Opthea is a biopharmaceutical company. Co. develops and commercializes therapies mainly for eye disease. Co.'s primary asset, OPT-302, is a soluble form of Vascular Endothelial Growth Factors (VEGF) Receptor-3 in clinical development as a therapy for wet (neovascular) age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Wet AMD and DME are the main causes of blindness in the elderly and diabetic populations respectively. Co.'s development activities are based on an intellectual property portfolio covering primary targets (VEGF-C, VEGF-D and VEGF Receptor-3) for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The OPT average annual return since 2020 is shown above.
The Average Annual Return on the OPT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OPT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OPT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|